DALLAS, Sept. 25, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring specialty drug maker Novadel Pharma Inc. (AMEX: NVD). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Novadel Pharma Inc. (AMEX: NVD) should be of particular interest to other drug delivery and formulation companies: Generex Biotechnology Corp. (Nasdaq: GNBT), CPEX Pharmaceuticals Inc. (Nasdaq: CPEX), Hospira Inc. (NYSE: HSP) and Acusphere Inc. (Pink Sheets:ACUS).

The full report is available at: http://www.stockpreacher.com/n/NVD

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

NovaDel Pharma Inc. (NVD), a specialty pharmaceutical company, engages in the development of new ways to deliver popular over-the-counter and prescription drugs. Its proprietary NovaMist technology enables rapid delivery of drugs into the bloodstream, which results to quicker onset of therapeutic effects and potential patient benefits in compliance, convenience and safety. Its proprietary delivery technology is focused on proven pharmaceuticals, targeting angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. While the Company works on developing its products independently, it also plans to collaborate with pharmaceutical and biotechnology companies to address unmet medical needs for a broad array of existing and future pharmaceutical products.

Message Board Search for NVD: http://www.boardcentral.com/boards/NVD

In the report, the analyst notes:

"Compared to conventional oral dosage forms, the Company's proprietary technology offer the potential benefit of faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly reduced first pass liver metabolism, which may result in lower doses. NVD's technology may also potentially improve patient convenience and adherence as the Company's oral sprays eliminate the requirement for water or the need to swallow.

"Sumatriptan's potential as an oral spray treatment with NVD's oral spray drug delivery technology was recently featured in a peer-reviewed journal Headache: The Journal of Head and Face Pain. NVD conducted two clinical trials with the goal of determining the drug's absorption across the oral mucosa, the pharmacokinetics and pharmacodynamic correlate of such pharmacokinetics in patients experiencing migraine attacks."

To read the entire report visit: http://www.stockpreacher.com/n/NVD

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.